Cirrhosis Discriminate Score (CDS) calculation.

<p>Cirrhosis Discriminate Score (CDS) calculation.</p

Non-invasive tests (NITs) values distribution at baseline and after an SVR.

<p>Non-invasive tests (NITs) values distribution at baseline and after an SVR.</p

Non-invasive tests (NITs) values before and after treatment.

<p>Non-invasive tests (NITs) values before and after treatment.</p

Median^# NIT values at post-SVR liver biopsy and reference cut-offs for the diagnosis of cirrhosis.

<p>Median<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0155967#t003fn001" target="_blank">^#</a> NIT values at post-SVR liver biopsy and reference cut-offs for the diagnosis of cirrhosis.</p

Patients' characteristics at the time of post-SVR liver biopsy.

<p>Patients' characteristics at the time of post-SVR liver biopsy.</p

Non-invasive Tests (NITs) values stratification according to post-SVR fibrosis stage.

<p>Non-invasive Tests (NITs) values stratification according to post-SVR fibrosis stage.</p

Demographic, clinical, and genetic features of subjects included in the study.

<p>(): % values; HCC: hepatocellular carcinoma; HCV: chronic hepatitis C virus infection, HBV: chronic hepatitis B virus infection (co-infected patients were considered in both categories), F: female, PNPLA3: patatin-like phosholipase domain-containing 3. p = 1.8×10⁻⁶ for the frequency distribution of the I148M polymorphism between HCC patients and controls.</p

Effect of I148M PNPLA3 variant on clinical presentation of HCC according to the etiology of liver disease (ALD & NAFLD vs. other etiologies).

<p>(): % values, {}: median and interquartile range. HCC: hepatocellular carcinoma, ALD: alcoholic liver disease, NAFLD: nonalcoholic fatty liver disease, F: female, PNPLA3: patatin-like phosholipase domain-containing 3. °Additive model. * Available in 353 patients, ** available in 413 patients. Very early HCC and advanced / terminal HCC were defined according to the updated Barcelona Clinic Liver Cancer (BCLC) staging system and EASL/EORTC guidelines <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0075982#pone.0075982-1" target="_blank">[1]</a>.</p

Kaplan-Meier estimates for survival in HCC patients subdivided according to the presence of homozygosity for PNPLA3 148M

<p>(p = 0.009 at Log-Rank test). Figures at the bottom refer to the number of patients still under observation at each time interval. HR: hazard ratio of death for homozygosity for the 148M allele, c.i.: confidence interval.</p

Independent predictors of death at multivariate Cox regression analysis in 356 patients with HCC with available follow-up subdivided according to the etiology of underlying liver disease (ALD & NAFLD vs. others).

<p>ALD: alcoholic liver disease, NAFLD: nonalcoholic fatty liver disease, Advanced stage: BCLC C-D, HR: hazard ratio of death, 95% c.i.: 95% confidence interval.</p